Efforts towards macrocyclic dihydrofolate reductase inhibitors

Vol. 1, 2019 - 109033
Poster only
Favorite this paper
How to cite this paper?
Abstract

Nontuberculous mycobacteria (NTM) are opportunistic pathogens responsible for pulmonary disease in immunocompromised patients or patients with pre-existing lung conditions such as bronchiectasis, cystic fibrosis or chronic obstructive pulmonary disease.1–3 Due to inefficient medicines, the incidence and prevalence of NTM pulmonary disease has increased worldwide.4–6 Based on the crystal structure of compound P218, a dihydrofolate reductase (DHFR) inhibitor developed for malaria,7 bond to Mycobacterium tuberculosis DHFR (tb-DHFR), and docking studies, we decided to design and investigate the activity of macrocyclic analogues against NTM. The key reactions to access the desired compounds are an alkylation reaction to connect the pyrimidine core to linker 2, a Mitsunobu reaction to connect the 2-hydroxyphenyl propanoic core to linker 1, a SN2 reaction to bind the pyrimidine to linker 1, and a Pd/Cu coupling to form the macrocycle with different ring sizes.

Institutions
  • 1 University of Campinas (UNICAMP) / Department of Organic Chemistry
  • 2 University of Campinas (UNICAMP) / Structural Genomics Consortium
Track
  • 2. Medicinal Chemistry of Synthetic Compounds
Keywords
Dihydrofolate reductase
macrocycles
antibiotics
nontuberculous mycobacteria